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Mitochondria, the powerhouse of the cell, play a critical role in several metabolic processes and apoptotic pathways. Multiple
evidences suggest that mitochondria may be crucial in ageing-related neurodegenerative diseases. Moreover, mitochondrial
haplogroups have been linked to multiple area of medicine, from normal ageing to diseases, including neurodegeneration.
Polymorphisms within the mitochondrial genome might lead to impaired energy generation and to increased amount of reactive
oxygen species, having either susceptibility or protective role in several diseases. Here, we highlight the role of the mitochondrial
haplogroups in the pathogenetic cascade leading to diseases, with special attention to Alzheimer’s disease.
1.Introduction
The mitochondrion is a membrane-enclosed cytoplasmic
organelle, which has evolved from a primitive aerobic
bacteria by means of a symbiotic relationship that started
1.5 billions years ago [1]. These organelles range from 0.5
to 10 micrometers (μm) in diameter and are composed of
compartments devoted to speciﬁc functions. These regions
include the outer membrane, the intermembrane space, the
inner membrane, the cristae, and the matrix. Mitochondria
aredescribedas“cellularpowerplants”becausetheyproduce
most of the cell’s supply of adenosine triphosphate (ATP)
[2], by means of the oxidative phosphorylation (OXPHOS)
machinery, which comprises electron transport chain (ETC)
and ATP synthase (complex V). The ETC provides the cell
with the most eﬃcient energetic outcome in terms of ATP
production. It consists of four multimeric protein complexes
(complex I to IV) located in the inner mitochondrial
membrane together with complex V [3].
Furthermore, mitochondria are key regulators of cell
survival and death. ETC dysfunction leads to reduced ATP
production, impaired calcium buﬀering, and increased gen-
eration of reactive oxygen species (ROS) [4]. Mitochondria
have their own DNA, the mitochondrial DNA (mtDNA),
representedbyacircularmoleculeof16.5kbwithoutintrons,
constituting of a heavy chain (H) and a light chain (L) [3, 5].
mtDNA carries 37 genes: 22 encoding for mitochondrial
transfer RNAs (tRNAs) (for the 20 standard amino acids,
plus an extra gene for leucine and serine), 2 for ribosomal
RNAs (rRNAs) and 13 encoding for polypeptides subunits
of complexes of the respiratory chain system, 7 of them
belonging to complex I or NADH dehydrogenase (ND1,
ND2, ND3, ND4, ND4L, ND5, ND6), 1 to complex III or
cytochrome c reductase, 3 to complex IV or cytochrome c
oxidase (COX I, COX II and COX III), and 2 to complex
V or ATP synthase (ATPase6 and ATPase8). These sub-
units are assembled together with nuclear-encoded subunits.
The remaining mitochondrial proteins, including all the
complex II subunits, are encoded by nuclear DNA. One
mitochondrion can contain two to ten copies of mtDNA.
Mitochondrial genetics diﬀers from Mendelian genetics in
three major aspects: maternal inheritance, heteroplasmy, and
mitotic segregation. Mitochondria are inherited in humans
via the female line [3, 5], transmitted as a nonrecombining
unit by maternal inheritance [6]. Furthermore, human
mtDNA is characterized by a much greater evolutionary rate2 International Journal of Alzheimer’s Disease
than that of the average of nuclear genes. Thus, its sequence
variation has been generated by the sequential accumulation
of new mutations along radiating maternal lineages. There-
fore, mtDNA contains a “molecular record” of the human
migrations. We can theoretically follow the transmission of
mtDNAfrom theoriginal“ancestormother”,the“mitochon-
drial Eve” [7], by identifying common polymorphisms that
have been accumulated with time. These common polymor-
phisms describe classes of continent-speciﬁc genotypes, the
haplogroups, evolved from the same ancestor, which can
be detected by restriction fragment length polymorphism
(RFLP) analysis. “Mitochondrial Eve” probably lived in
Africa about 200,000 years ago and phylogeographic studies
allowed to identify the mtDNA haplogroups tree and the
mtDNA migration route (see Figure 1). Because the process
of molecular diﬀerentiation is relatively fast and occurred
mainly during and after the recent process of dispersal
into diﬀerent parts of the world, haplogroups usually
tend to be restricted to particular geographic areas and
populations.
The basal branching structure of mtDNA variation in
most parts of the world is now well understood [6]. The
major branches of the tree were usually restricted geograph-
ically, some to sub-Saharan Africans, others to East Asians
and yet others to Europeans and Near Easterners [8]. African
haplogroups fall into seven major families (L0, L1, L2, L3,
L4, L5, L6). About 85000 years ago, probably in the Horn of
Africa, changes in climate, the glacial interstadial phase 21,
triggered the rising of many descendant haplogroups from
the root of haplogroup L3, the ﬁrst multifurcation node,
probably because of some colonization event or local pop-
ulation growth [6, 9, 10]. Non-African mtDNA (excluding
migrations from Africa within the past few thousand years)
descendfromL3andbelongeithertotheMorNsuperclades.
Haplogroup N soon gave rise to haplogroup R. In the Indian
subcontinent and in Southeast Asia there is the richest basal
variation in the three founder haplogroups M, N, and R, and
this suggests a rapid colonization along the southern coast
of Asia, about 60000 years ago [6]. Over 30 subclades of the
haplogroup M are present in Asia. Haplogroups A, B, C, D,
and Xhavebeen found in theAmericas, comingmainly from
Asia.The expansionsnorthwards occurredlater,about45000
years ago when technology and climatic conditions enabled
the exploration of the interior of Eurasia. One of the more
marginal extensions eventually led to the peopling of Europe
[6].
In Europeans and Near Easterners (who share a rather
recent common ancestor), nine diﬀerentmitochondrial hap-
logroups have been identiﬁed (H, I, J, K, T, U, V, W, X). The
variation in the basal European mtDNA haplogroups dates
to about 45000 years ago [6]. European mtDNA variation
is surprisingly impoverished in the number of independent
basal lineages, compared with the South Asian mtDNA
variation, maybe for the peripheral role that the pioneer
migration into the Near East and subsequently Europe
must have had in the broader “Out-of-Africa” scenario.
Complete mtDNA sequencing and the increasing number
of samples analyzed allowed subdividing haplogroups in
smaller groups identifying younger branches on the mtDNA
evolution tree. Therefore, subhaplogroups classiﬁcation is
continuously evolving [6].
2.Mitochondrial Haplogroups andMedicine
It has been supposed that genetic polymorphisms within
the mitochondrial genome might lead to impaired energy
generation and to increased amount of ROS, causing subtle
diﬀerences in the encoded proteins and, thus, minimum
changes in mitochondrial respiratory chain OXPHOS activ-
ity and free radical overproduction. Increased production of
ROS damages cell membranes and further accelerates the
high mutation rate of mtDNA. The mtDNA is particularly
susceptible to oxidative damage. Because of its vicinity
with ROS source (ETC) and because it is not protected by
histones and it is ineﬃciently repaired, mtDNA shows a high
mutationrate.AccumulationofmtDNAmutationsenhances
normal ageing, leads to oxidative damage, and causes energy
failure and increased production of ROS, in a vicious cycle.
This could predispose to diseases or modify longevity in
individual or in a population sharing the same mtDNA
genotype.Maybe the opposite couldbe also true for diﬀerent
polymorphism(s), which could be protective.
Severalstudiescorrelatemitochondrialhaplogroupswith
disease’s susceptibility or confer them protective roles. In
a study of 2008, conducted on 114 healthy Spanish males,
Marcuello et al. [11] found that haplogroups J presents with
lower VO(2max) (oxygenconsumption) than non J variants.
J has been related with a lower eﬃciency of ETC, diminished
ATP, and ROS production. Furthermore, the lower ROS
production associated to J could also account for the accrual
of this variant in elderly people consequent to a decreased
oxidative damage [11]. The H haplogroup seemed to be
responsible for the diﬀerence between J and non-J, and this
group also had signiﬁcantly higher mitochondrial oxidative
damage than the J haplogroup, suggesting that ROS produc-
tion is responsible for the higher VO(2max) found in this
variant [12]. In agreement with these results, VO(2max) and
mitochondrial oxidative damage were positively correlated.
Supporting the hypothesis that J haplogroup may impair the
OXPHOS coupling, Pierron et al. [13]d e m o n s t r a t e dt h a t
J haplogroup was markedly underrepresented among the
A3243G mutation carriers. This mutation on the tRNALeu
gene (UUR) is one of the most common mtDNA mutation.
The phenotypicexpression of this mutation is quite variable,
ranging from mild to severe clinical phenotypes (MELAS).
The authors, in order to explain the epidemiology of
haplogroup J and A3243G mutation speculated that this
association is lifethreatening, and therefore lethal to the
embryo or germ line [13].
One of the most common manifestation of some
mitochondrial disease is the presence of retinal pigmentary
changes, which are similar to those observed in age-related
maculopathy (ARM). Jones et al. [14]d e m o n s t r a t e da n
association between haplogroup H and a reduced prevalence
of this disease, after adjusting for known ARM risk factors.
Haplogroup H1 may be protective for ischemic stroke; in
fact, it was found to be signiﬁcantly less frequent in stroke
patientsthanin controls, whencomparing eachcladeagainstInternational Journal of Alzheimer’s Disease 3
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Figure 1: MtDNA haplogroup migration patterns. The map shows the migration patterns of the main mtDNA haplogroups.
all other haplogroups pooled together, in a paper of Rosa
et al. [15] focusing on 534 ischemic stroke patients and 499
controls.
In a prospective study of intensive care patients in
Newcastle-upon-Tyne conducted by Baudouin et al. [16],
haplogroup H seemed to confer an increased chance of
long-term survival after sepsis than non-H haplogroups
(primarily the closely-related haplogroups J and T) maybe
for the linkage between mitochondrial dysfunctions and
sepsis-induced multipleorgan failuredemonstrated byProtti
and Singer [17]. Two possibilities have been proposed:
haplogroup H might protect through greater heat genera-
tion (because of higher electron transport rates or looser
coupling) [16], or through greater ROS production (because
of tighter coupling and raised protonmotive force), which
could reduce bacterial infection [18, 19]. Haplogroup R also
was a strong independent predictor for survival advantage
in severe sepsis with an important impact on long-term
clinical outcome [20]. Haplogroup H has been associated
with high spermatozoa motility, haplogroup T, instead, with
asthenozoospermia, showing signiﬁcant diﬀerences in their
OXPHOS performance [21]. However Pereira et al. [22]
did not conﬁrm these ﬁndings demonstrating no systematic
diﬀerences between haplotypes from asthenozoospermic
samples and those from population surveys. Haplogroup T
could be related, instead, with a lower capacity to respond
to endurance training, appearing as a marker negatively
associated with the status of elite athletic endurance [23].
Within the Western European, haplogroup J, was asso-
ciated with 80% decrease in the risk of progression to
neuroretinal disorder [24]. Haplogroups U and K were
independently associated with a higher prevalence of age-
related hearing loss as described by Manwaring et al. [25]
on 912 patients of the Blue Mountains Eye Study cohort.
mtDNA haplogroup U, in mitochondrial patients carrying
mtDNA single macrodeletion, is associated with a higher
relative risk of developing pigmentary retinal degeneration,
short stature, dysphasia-dysarthria and cardiac conduction
defects, modulating the clinical expression of mitochondrial
encephalomyopathies due to mtDNA macrodeletions [26].
mitochondrial dysfunctions have long been hypothesized to
be involved in tumorigenesis. Supporting such idea, changes
in the number, shape, and function of mitochondria but
also mutations in both the noncoding and coding regions
of the mtDNA have been reported in various types of
cancers [27–29]. In a recent study conducted in China,
Fang et al. [30] found that macrohaplogroup M and its
subhaplogroup D5 had an increased frequency in breast
cancer patients relative to controls but haplogroup M was
decreased in the metastatic group; macrohaplogroup N are
more likely to exhibit metastatic tumors. Haplogroup D4a
was associated with an increased risk of thyroid cancer, while4 International Journal of Alzheimer’s Disease
Table 1: A complete list of published researches focusing on mtDNA haplogroups and neurodegenerative diseases.
Reference Number of
patients
Number of
controls
Haplogroups that
increase risk
Haplogroups that
reduce risk
Sample’s region of
origin
Parkinson’s
disease
Van der Walt et al. [40] 609 340 None
J in females, K in
individuals older than
70 years
Europe
Autere et al. [42] 238 183
supercluster JTIWX
increase risk both in
Parkinson disease and
in Parkinson with
dementia
None Finland
Pyle et al. [41] 455 447 None cluster UKJT United Kingdom
Ghezzi et al. [43] 620 1486 None K Italy
Latsoudis et al. [44] 224 383 None
trend for haplogroups
J, T, U and I and the
supercluster of
haplogroups UKJT to
be slightly
underrepresented in
PD patients
Crete
Takasaki,[79] 96 96 M7b2, B4e, and B5b None Japan
Simonet al. [45] 168 families 895 None None USA (non Hispanic
Caucasian)
Amyotrophic
lateral sclerosis
Mancuso et al. [46] 222 151 None I Italy
Chinnery et al. [47] 504 493 None None United Kingdom
Friedreich’s
ataxia Giacchetti et al. [48]9 9 4 8 N o n e
N o .H o w e v e r ,p a t i e n t s
with haplogroup U
have a delay of 5 years
in the disease onset and
al o w e rr a t eo f
cardiomyopathy
Italy
Huntington’s
disease
Mancuso et al. [49] 51 181 None None Italy
Arning et al. [50] 404 48
haplogroup H
associated with a lower
age of onset
None Germany
Multiple
sclerosis
Kalman et al. [51] 77 84 K and J None Caucasian
Otaegui et al. [52] unknown unknown unknown
trend for haplogroups
JT to be slightly
underrepresented in
PD patients with
multiple sclerosis and
multiple sclerosis with
optic neuritis
Basque country
Yu et al. [53] >2500 >2500 J, 13708A variant None
Europe (Norway,
Spain, Germany,
Sardinia, Finland)
Ban et al. [54] 994 1506
trend for haplogroup U
to be overrepresented
in patients with
multiple sclerosis
None United Kingdom
Ghabaee et al. [55]5 2 N o n e
Haplogroup A
associated with lower
age of onset and
haplogroup H
associated with optic
nerve involvement
None IranInternational Journal of Alzheimer’s Disease 5
Table 1: Continued.
Reference Number of
patients
Number of
controls
Haplogroups that
increase risk
Haplogroups that
reduce risk
Sample’s region of
origin
Alzheimer’s
disease
Chagnon et al. [74]6 9 8 3 J T Q u e b e c , C a n a d a
Carrieri et al. [77] 213
179 age-
matched
and 210
individuals
aged more
than
100 years
None
K and U seem to
neutralize the risk
eﬀect of the APOE ε4
allele
Italy
Van der Walt et al. [75] 989 328 U in males U in females Europe
Pyle et al. [41] 185 447 None None United Kingdom
Elson et al. [78] 145 128 None None
United Kingdom
and United States
(European descent)
Mancuso et al. [56] 209 191 None None Italy
Fesahat et al. [76] 30 100 H and U None Iran
Takasaki,[79] 96 96 G2a, B4c1 and N9b1 None Japan
Maruszak et al. [80] 222 252 HV None Poland
Tanaka et al. [84] 153 129
np956-965 poly-c
insertion and 856A>G
variant
None Japan
Santoro et al. [81] 936 776
H5, especially in
subjects younger than
75 years old
None Italy
no signiﬁcant correlation has been detected between any
mtDNA haplogroups and colorectal cancer. These evidences
suggest that mitochondrial haplogroups may have a tissue-
speciﬁc, but also population-speciﬁc and stage-speciﬁc role
in modulating cancer development[30].
3.Haplogroupsand Aging
In 1992, Harman [31] ﬁrst proposed the “mitochondrial-
free-radical hypothesis”, a mitochondrial theory of aging,
supposing that accumulation of damage to mitochondria
and mtDNA leads to aging of humans and animals and
aﬀects longevity. The observation that mitochondrial func-
tiondeclinesandmtDNAmutationincreasesintissuecellsin
an age-dependent manner supported his theory. Age-related
impairment in the respiratory enzymes not only decreases
ATP synthesis but also enhances production of ROS through
increased electron leakage in the respiratory chain [31]. The
association between longevity and mtDNA haplogroups has
been long reported [32–34]. This association is probably
population-speciﬁc, being evident in centenarians from
northern Italy (haplogroup J increase the individual chance
to attain longevity) but not in those from southern Italy
[34]. In nonagenarians/centenarians from Ireland, Finland,
and Japan, mtDNA haplogroups and longevity are also
associated. In a recent investigation on longevity in a
Japanese population, haplogroup D4b2b, D4a, and D5 have
been found associated with centenarians (over 100 years-of-
age) and haplogroup D4a with semisupercentenarians (over
105 years-of-age) [35], while another variant (mt9055A,
haplogroup UK)was found to be signiﬁcantly more frequent
in French centenarians [36]. A higher frequency of the
J haplogroup and a signiﬁcantly high frequency of three
mtDNA polymorphisms (150T, 489C, 10398G) have also
been reported in Finnish long-lived subjects [37]. Castri
and colleagues [38] found that the 5178A mutation in
haplogroupDisassociated withdecreasedlongevity,whereas
the 150T mutation is associated with increased longevity in
152 subjects from Costa Rica [38].
4.Haplogroupsand Neurodegeneration
Oxidative “free radical” damage is therefore involved in
normal aging, but it is also generally viewed as an etiological
cause of tissue degeneration, and ROS damage has been
reported within speciﬁc brain regions in many neurode-
generative conditions [39]. Basing on the evidence that
mtDNA variations lead to diﬀerent OXPHOS performance,
than to diﬀerent oxidative stress proﬁle, the association
between haplogroups and neurodegenerative disorders has
been long investigated (see Table 1). Van der Walt et al. [40]
observed that haplotypes J and K reduced the incidence of
Parkinson’s disease (PD) by 50%. A further analysis revealed
that the SNP at 9055A of ATP6 (which deﬁnes haplogroup
K) reduced the risk in women, and the SNP at 13708A
of ND5 gene was protective in individuals older than 70
years (haplogroup J) [40]. The cluster UKJT was associated
with a 22% reduction in risk for PD but not with risk of
Alzheimer’s disease (AD), conﬁrming that the association
with PD was disease-speciﬁc and not a general eﬀect seen in6 International Journal of Alzheimer’s Disease
all neurodegenerativediseases [41].The superclusterJTIWX,
indeed, increased the risk of both PD and PD with dementia.
This cluster was associated with a twofold increase in
nonsynonymous substitutionsinthemtDNAgenesencoding
complex I subunits [42]. In a large cohort of 620 Italian
PD patients, haplogroup K was associated with a lower risk
for PD [43]. In contrast to these evidences, Latsoudis et al.
[44] did not observe mtDNA haplogroups that predisposed
to PD in 224 PD patients and 383 controls from Crete.
A recent study of 2010 [45] conducted on 168 multiplex
PD families in which the proband and one parent were
diagnosed with PD and 895 controls, in order to investigate
the potential contribution of mtDNA variants or mutations
to the risk of PD, found no signiﬁcant diﬀerences in the
frequencies of mitochondrial haplogroups or of the 10398G
complex I gene polymorphism in PD patients compared to
controls, and no signiﬁcant associations with age of onset of
PD. Mitochondrial haplogroup and 10398G polymorphism
frequencies were similar in probands having an aﬀected
father as compared to probands having an aﬀected mother.
To investigate if speciﬁc genetic polymorphisms within
the mtDNA could act as susceptibility factors and contribute
to the clinical expression of sporadic amyotrophic lateral
sclerosis (ALS), our group genotyped predeﬁned European
mtDNA haplogroups in 222 patients of clear Italian origin
withsporadicALSand151matchedcontrols[46].Mutations
on the entire SOD1 gene were excluded. The frequency of
haplogroups I resulted lower in ALS cases than in controls.
Age of onset, severity, and neurological system involved
in the disease did not associate with haplogroups. In a
comparison developed to test what makes this haplogroup
Id i ﬀerent from the other haplogroups tested, we found
highly signiﬁcant diﬀerence in 16391A and 10034C alleles.
In accordance with the described study, mtDNA polymor-
phisms might contribute to motor neuron degeneration,
possibly interacting with unknown genetic or environmental
factors [46]. However, this ﬁnding was not conﬁrmed by
Chinnery et al. [47], who studied large UK cohort of 504
ALS patients and 493 controls and found no evidence that
mtDNA haplogroups contribute to the risk of developing
ALS.
As far as regard Friedreich’s ataxia (FA), Giacchetti et al.
[48] studied 99 FA patients and 48 control individuals, all
from southern Italy revealing that patients with haplogroup
U class had a delay of 5 years in the disease onset and a lower
rate of cardiomyopathy. However, no signiﬁcant diﬀerence
was found in the frequency distribution of haplogroups
between patients and controls [48].
Huntington’s disease (HD), as FA, is a trinucleotide
expansion disorder, caused by a CAG expansion in the IT15
gene. On the basis of the Giacchetti’s report [48], we wanted
to determine whether mtDNA polymorphisms play the role
of “modiﬁer genes” in HD. In this work, we have genotyped
51 patients with HD and 181 matched controls. Only HD
subjects with a similar number of triplets (49.3 ± 5.3, range
45–60) were enrolled. The frequency of the haplogroups and
haplogroup clusters did not diﬀer between the two groups,
and we did not observe correlation with gender, age of
onset, and disease status. Over the last 3 years, patients have
undergone prospective evaluations, with a control every 6
months. Diﬀerent functional scales have been performed.
No signiﬁcant diﬀerence was observed between diﬀerent
haplogroups and haplogroup clusters in the cognitive or
motor progression of the disease. Therefore, our study did
not support the association between mtDNA haplogroup(s)
and HD [49]. However, in a recent study, Arning and
colleagues demonstrate a signiﬁcantly lower age at onset in
patients carrying the most common haplogroup H [50].
Several lines of evidence suggest that mitochondrial
genetic factors may inﬂuence susceptibility to multiple
sclerosis (MS). Large scale screening of the mtDNA revealed
no pathogenic mutations but an association between hap-
logroups K and J with MS in Caucasians [51]. Another
study reported that none of the haplogroups were associated
with the disease. There seemed to be a protective trend
in the “JT + the protective allele of UCP2” combination
[52]. More recently, Yu and colleagues [53]o b s e r v e dt h a t
the frequency of haplogroup J was higher in patients than
in controls. 13708A variant itself seemed to explain this
association and might represent a susceptibility allele for MS
[53]. In the same year a study of Ban et al. [54] performed
in order to explore this hypothesis further, resequenced
the mitochondrial genome from 159 patients with MS and
completed a haplogroup analysis including a further 835
patients and 1,506 controls. Haplogroup analysis identiﬁed
a trend towards an overrepresentation of superhaplogroup
U. In addition they also found modest evidence of an
association with variations in the nuclear gene NDUFS2
[54]. In 2009, Ghabaee and coauthors studied mtDNA
haplogroups, age, gender, clinical disability, course of the
disease, and presenting symptoms of 52 MS patients. The
prevalentmutationswereJ,L,andThaplogroups.Haplotype
A was more prevalent in patients with younger age of onset
and high proportion of haplogroup H was associated with
optic nerve involvement. No motor symptoms were seen in
haplogroup H patients [55].
5.Haplogroupsand Alzheimer’s Disease
ADisa brainneurodegenerativedisordernamed forGerman
physician Alois Alzheimer, who ﬁrst described it at a
scientiﬁc meeting in November 1906, presenting the case
of “Frau Auguste D.” a 51-year-old woman brought to see
him in 1901 by her family. Approximately 2-3% of AD
cases are early onset and familial, with autosomal dominant
inheritance. Mutations in three genes are known to cause
familial AD: mutations in the gene of amyloid precursor
protein (APP), which is leaved sequentially by b- and c-
secretases, and mutations in genes of presenilins 1 and 2
(PS1 and PS2), one or other of which is a component of
eachc-secretasescomplex.Althoughthese speciﬁcmutations
have been associated with the relatively rare forms of familial
AD, the causes of the much more frequently occurring
sporadic AD remain unknown, and the mechanisms leading
to neuronal death are still unclear [56]. Most forms of
sporadic late-onset AD have probably a complex aetiology
due toenvironmental and genetic factors, which takenalone,
are not suﬃcient to develop the disease. Presently, age isInternational Journal of Alzheimer’s Disease 7
the major risk factor for sporadic AD, while the genetic
major risk factor is recognized in the presence of allele ε4o f
apolipoprotein E (ApoE4) [57]. However, in the majority of
late-onset AD patients, the casual factors are still unknown
and genetics factor probably interact with environmental
factors or with other pathologic or physiologic conditions
to exert the pathogenic eﬀect, such as chronic inﬂammation
[58], excitotoxicity damage [59], oxidative stress [60], and
diminished brain metabolism [61]. To date, the “amyloid-
β cascade” hypothesis, ﬁrst proposed in 1992 [62], remains
the main pathogenetic model of AD. However, although
this cascade is potentially viable in familial AD cases with
mutation in APP and PS genes, its role in the sporadic AD
is unclear [63].
Although the pathogenic mechanisms of neurodegener-
a t i o ni nA Da r en o tc l a r i ﬁ e d ,i nt h ep a s t1 5y e a r s ,n u m e r o u s
studies have been performed in order to better understand
the possible involvement of mitochondria, accumulating
evidences suggesting that mitochondrial dysfunction and
oxidative stress occur in brain and peripheral tissues of AD
patients and supporting the idea that mitochondria may
trigger the abnormal onset of neuronal degeneration and
death in AD [56].
In order to study the importance and potential causes
of mitochondrial dysfunction, the cytoplasmic hybrid
(“cybrid”) technique, a technique in which mitochon-
dria/mtDNA from human AD and control platelets is
transferred to culturable cells depleted of endogenous
mtDNA [64], has been applied. The resulting AD cybrids
showed a transferred COX defect and revealed a number
of consequences that recapitulate the pathology observed
in AD brain [65–67]. Remarkably, AD cybrid lines had
increased intracellular amyloid accumulation and increased
amyloid secretion [65], as well as an increased proportion
of morphologically abnormal mitochondria [68]. Trimmer
et al. [67] observed that AD cybrid lines show a bioenergetic
defect that becomes more severe with passage in culture.
AD cybrids also showed elevated spontaneous death with
apoptotic nuclear morphology [69], increased cytoplasmic
cytochrome c levels and caspase-3 activity [65], and elevated
cleavage of caspase substrate [69] not observed in non-AD
cybrids. Again, the spontaneous alterations in cell death and
cell-death pathways observed spontaneously in AD cybrids
canbereproducedbyexposingnon-ADcybridstoexogenous
aggregated beta amyloid or oxidative stress [69, 70]. Despite
these reports, a number of technical issues have confounded
cybrid studies [71, 72]. However, these studies on cybrid
models reinforce the concept that primary mtDNA changes
could be responsible for the “mitochondrial features” of
sporadic AD and could be the origin of the increased
oxidative stress and Aβ deposition found in sporadic AD
brain.
With the aim of better clariﬁng the involvement of
mitochondria in the pathogenesis of AD, it has studied
the possible association of mitochondrial haplogroups and
AD susceptibility. As already discussed, inherited European
mitochondrial haplogroups may be related to longevity [37,
73], as well as to neurodegeneration, AD risk, and, thus,
death in Caucasians. In a paper of Chagnon et al. [74],
haplogroup T is described underrepresented in AD, while
haplogroup J overrepresented [74]. Van der Walt et al. [75]
showed that males classiﬁed as haplogroup U had a signif-
icant increase in risk of AD, while females demonstrated
a signiﬁcant decrease in risk with the same U haplogroup.
To assess the relationship between mtDNA haplogroup and
AD in an Iranian population, Fesahat sequenced the two
mtDNA hypervariable segments in 30 AD patients and 100
control subjects. They found that haplogroups H and U are
signiﬁcantly more abundant in AD patients, assuming that
these two haplogroups might act synergistically to increase
the penetrance of AD disease [76]. By studying an Italian
sample of subjects, Carrieri et al. [77] hypothesized that
K and U haplogroups may act by neutralizing the eﬀect
of the major AD risk factor ApoE ε4 allele. However, this
association was not conﬁrmed recently by a collaborative
study performed by Elson et al. [78], in which the authors
analyzed the complete mtDNA coding region sequences
from more than 270 AD patients and normal controls.
The authors described no statistically signiﬁcant association
between haplogroup and disease status. They also observed
that for both synonymous and nonsilent changes, the overall
numbers of nucleotide substitutions were the same for the
AD and control sequences.
Regarding our experience, in our laboratory we did not
ﬁnd any evidence for an etiological role of haplogroups in
AD risk [56]. We studied the frequency of the European
mtDNAhaplogroupsinaclinicallywell-deﬁnedgroupof209
unrelated patients and 191 controls, both with clear Tuscan
origin (in order to minimize the risk of false associations
between gene markers and disease). The frequency of
haplogroups was not signiﬁcantly diﬀerent between the two
groups. Furthermore, there was no signiﬁcant diﬀerence
between genders as far as mtDNA haplogroups distribution
in both AD patients and control groups is concerned.
Takasaki, studying a Japanese population of 96 AD patients,
described an association between AD and the haplogroups
G2a,B4c1,andN9b1.Inaddition,tocomparemitochondrial
haplogroups of the AD patients with those of other classes
of Japanese people, the relationships between four classes of
Japanese people (96 Japanese centenarians, 96 Parkinson’s
disease (PD) patients, 96 type 2 diabetic (T2D) patients,
and 96 nonobese young males) and their haplogroups are
also described. The four classes of people are associated with
a set of haplogroups, therefore diﬀerent from those of the
AD Japanese patients [79]. A study conducted on a Polish
population found that HV cluster is signiﬁcantly associated
withtheriskofAD,regardless oftheAPOE4status,reporting
no evidence for the involvement of haplogroup U, K, J, or T
in AD risk [80].
The most recent report abouta possible link between AD
and mtDNA genotypes shows evidence for subhaplogroup
H5 as a risk factor for late onset AD [81]. Santoro et al.
analyzed 936 AD patients and 776 controls comparable
for age and ethnicity from the central-northern regions of
Italy. Haplogroups H3, H4, H5, and H6 [82] are associated
with an increased production of ROS than those with
haplogroup T. Accordingly, it was hypothesized that subjects
with haplogroup H could be more prone to oxidative stress8 International Journal of Alzheimer’s Disease
than those with other haplogroups [18], and consequently
more susceptible to neurodegenerative diseases. They found
that subhaplogroup H5 appears to be associated with a
higher risk of AD in both the total sample and the female
group. They also found that subhaplogroup H5 interacts
w i t ha g ei nm o d i f y i n gA Dr i s k ;i nf a c tH 5s u b j e c t sy o u n g e r
than 75years oldhad a higher AD risk than non-H5subjects.
Age is a strong risk factor for AD [83]a n dt h ea u t h o r s
hypothesized that age 75 could be considered as a threshold,
under which risk factors such as subhaplogroup H5 and
APOE could independently exert their major eﬀect on the
development of the disease, while over this age, other risk
factors, such as ageing itself, would largely prevail. Tanaka
and colleagues also agree that inherited mtDNA common
polymorphisms could not be the single major causes of AD
but that some rare variants in the protein-coding-region
m a yh a v ep r o t e c t i v ee ﬀects for high-risk populations with
the APOE ε4 allele. The authors however indicate that the
np956-965 poly-c insertion and 856A>Gv a r i a n tm i g h tb ea
risk factor for AD [84].
6.Conclusions
In the past 15 years, research has been directed at clarifying
the involvement of mitochondria and defects in mitochon-
drial oxidative phosphorylation in several disorders. It has
been speculated that mtDNA mutations that accumulate
with age might lead to impaired energy generation and to
increased amount of ROS, both resulting in cell damage.
Polymorphisms in mtDNA may cause subtle diﬀerences in
mitochondrial respiratory chain activity and free radical
overproduction. This could predispose an individual, or
a population sharing the same mtDNA genotype, to an
earlier onset of apoptotic processes, such as accumulation of
somatic mtDNA mutations and mitochondrial impairment.
The opposite could be true for diﬀerent polymorphism(s),
which could be beneﬁcial increasing mitochondrial respira-
tion and/or reducing ROS production [57, 85]. A critical
role for mitochondrial dysfunction and oxidative damage
in neurodegenerative diseases has been greatly strengthened
by recent ﬁndings. However, despite the morphological
and biochemical evidence of mitochondrial dysfunctions
in various tissues of patients with neurodegenerative dis-
orders, the role of the mitochondrial genome and of
its haplogroups as a risk factor is still debated. MtDNA
haplogroups havebeen associated with a number ofdiﬀerent
neurodegenerative diseases, but to date, the only disease
consistently associated with a diﬀerent mtDNA haplogroup
frequency is PD. Although it has been suggested that
inherited haplogroups K and U may inﬂuence AD risk in
Caucasians, this is still an unresolved question. To date,
mtDNA haplogroups do not seem to play a major role
in AD. The mtDNA alterations that cybrid models induce
to hypothesize might be due to somatic factors. APP, Aβ-
induced mitochondrial toxicity, oxidative stress, somatic
mtDNA damage, mitochondrial dysfunction and apoptosis
seem to be interconnected in vicious manner that reinforces
this dysfunction by causing mtDNA damage, impairment of
the mitochondrial respiration and oxidative stress leading to
neurodegeneration and dementia. Researches performed in
order to allow the identiﬁcation of AD risk factor also in
preclinicalstagesmightbeusefulinthedevelopmentofmore
eﬀective therapeutic interventions at a potentially reversible
stage.
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